GlassScriptPhysician profile
Annette R Lavender
NPI 1710191713
$11,322.59
in general payments reported to CMS, 2019-2025
32 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,337 · 2022: $2,424 · 2023: $2,870 · 2024: $2,303 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,562.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,780.22 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,625.65 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,102.75 | 2021-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,092.22 | 2021-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $880.46 | 2021-2025 | |
| Lilly USA, LLC | $811.72 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $557.19 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $552.86 | 2022-2025 | |
| Pfizer INC. | $497.84 | 2021-2024 | |
| Esperion Therapeutics, INC. | $387.25 | 2021-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $322.46 | 2022 | |
| Exact Sciences Corporation | $294.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $182.79 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $162.81 | 2021-2023 | Belsomra, Gardasil 9, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $158.32 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $135.01 | 2021-2023 | Rexulti |
| Medtronic, INC. | $129.92 | 2021 | |
| Acadia Pharmaceuticals INC | $111.70 | 2024 | Daybue |
| Nestle Healthcare Nutrition INC. | $105.21 | 2021-2023 | |
| Dexcom, INC. | $96.84 | 2021-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $81.89 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $48.11 | 2022 | |
| Idorsia Pharmaceuticals US INC | $40.04 | 2022-2023 | Quviviq |
| Imperative Care, INC | $36.91 | 2024 | Symphony Catheter |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.95 | 2024 | Cabtreo |
| Horizon Therapeutics Plc | $17.74 | 2021 | |
| Amgen INC. | $16.60 | 2021 | |
| Inspire Medical Systems, INC. | $16.33 | 2025 | Inspire |
| Pharming Healthcare, INC. | $14.95 | 2023 | Ruconest |
| Daiichi Sankyo INC. | $14.78 | 2022 | |
| Sanofi Pasteur INC. | $14.63 | 2023 | |
| Dynavax Technologies Corporation | $8.39 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Lavender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.